OrbiMed

OrbiMed is a global investment firm exclusively focused on the healthcare industry. The firm seeks to invest in world-class healthcare companies to drive innovation, address unmet medical needs, and improve patient outcomes. Their investment scope spans the entire healthcare spectrum, including biopharmaceuticals, medical devices, digital health, diagnostics, drug discovery tools, and healthcare services. OrbiMed provides tailored financing solutions and leverages its extensive global team resources to help build and scale its portfolio companies.

The investment business of OrbiMed was founded in New York City in 1989. Over the years, the firm has expanded its global footprint, opening offices in San Francisco and Shanghai in 2007, Herzliya in 2010, Hong Kong in 2017, and London in 2023. OrbiMed manages approximately $20 billion across public and private company investments worldwide, demonstrating a long-standing commitment to the healthcare sector.

OrbiMed invests across various stages, from seed-stage venture capital to large publicly-traded corporations, utilizing three primary strategies: public equity, private equity, and private credit/royalty. Their private equity approach is flexible, often taking a lead investor role to help portfolio companies become market leaders. Notable companies within their portfolio include ADARx, which is developing an RNA targeting platform for therapeutics; Treeline Biosciences, focused on targeted oncology drug discovery; Mirador Therapeutics, redefining immunology and inflammation; Adaptive, a leader in measurable residual disease testing for lymphoid cancers; Biokin, developing antibody and ADC oncology therapies; and Avenzo Therapeutics, focused on next-generation oncology therapies.

The firm's strength lies in its team of over 150 distinguished professionals, encompassing scientific, medical, and investment expertise. This diverse team collaborates across public and private equity and credit teams, fostering shared insights and comprehensive support for their portfolio companies. OrbiMed is committed to responsible and sustainable growth, integrating environmental, social, and governance (ESG) factors into its investment due diligence process to build long-term shareholder value and deliver new cures.